Antovic A - Search Results

1

Studies of microparticles in patients with the antiphospholipid syndrome (APS).

Vikerfors A, Mobarrez F, Bremme K, Holmström M, Ågren A, Eelde A, Bruzelius M, Antovic A, Wallén H, Svenungsson E. Vikerfors A, et al. Among authors: antovic a. Lupus. 2012 Jun;21(7):802-5. doi: 10.1177/0961203312437809. Lupus. 2012. PMID: 22635239

2

The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism.

Antovic A, Blombäck M, Bremme K, He S. Antovic A, et al. Blood Coagul Fibrinolysis. 2002 Apr;13(3):181-6. doi: 10.1097/00001721-200204000-00002. Blood Coagul Fibrinolysis. 2002. PMID: 11943930

3

Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?

Antovic JP, Rafik Hamad R, Antovic A, Blombäck M, Bremme K. Antovic JP, et al. Among authors: antovic a. Thromb Haemost. 2002 Oct;88(4):644-7. Thromb Haemost. 2002. PMID: 12362237

4

Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.

Antovic JP, Yngen M, Ostenson CG, Antovic A, Wallen HN, Jorneskög G, Blombäck M. Antovic JP, et al. Among authors: antovic a. Blood Coagul Fibrinolysis. 2003 Sep;14(6):551-6. doi: 10.1097/00001721-200309000-00006. Blood Coagul Fibrinolysis. 2003. PMID: 12960608

5

Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance.

Antovic A, Blombäck M, Bremme K, Van Rooijen M, He S. Antovic A, et al. J Thromb Haemost. 2003 Dec;1(12):2531-5. doi: 10.1111/j.1538-7836.2003.00451.x. J Thromb Haemost. 2003. PMID: 14675088 Free article.

6

Marked increase of fibrin gel permeability with very low dose ASA treatment.

Antovic A, Perneby C, Ekman GJ, Wallen HN, Hjemdahl P, Blombäck M, He S. Antovic A, et al. Thromb Res. 2005;116(6):509-17. doi: 10.1016/j.thromres.2005.02.007. Thromb Res. 2005. PMID: 16181986

7

Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma.

Antovic A, Blombäck M, Sten-Linder M, Petrini P, Holmström M, He S. Antovic A, et al. Blood Coagul Fibrinolysis. 2005 Nov;16(8):585-96. doi: 10.1097/01.mbc.0000188411.94740.d7. Blood Coagul Fibrinolysis. 2005. PMID: 16269934

8

Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.

Tehrani S, Mobarrez F, Antovic A, Santesson P, Lins PE, Adamson U, Henriksson P, Wallén NH, Jörneskog G. Tehrani S, et al. Among authors: antovic a. Thromb Res. 2010 Sep;126(3):e225-31. doi: 10.1016/j.thromres.2010.05.023. Epub 2010 Jul 15. Thromb Res. 2010. PMID: 20637495 Clinical Trial.

9

Changes in von Willebrand factor and ADAMTS13 during IVF.

Westerlund E, Antovic A, Hovatta O, Eberg KP, Blombäck M, Wallén H, Henriksson P. Westerlund E, et al. Among authors: antovic a. Blood Coagul Fibrinolysis. 2011 Mar;22(2):127-31. doi: 10.1097/MBC.0b013e32834363ea. Blood Coagul Fibrinolysis. 2011. PMID: 21192251

10

Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.

Mobarrez F, He S, Bröijersen A, Wiklund B, Antovic A, Antovic J, Egberg N, Jörneskog G, Wallén H. Mobarrez F, et al. Among authors: antovic a, antovic j. Thromb Haemost. 2011 Aug;106(2):344-52. doi: 10.1160/TH10-12-0810. Epub 2011 May 26. Thromb Haemost. 2011. PMID: 21614411 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

77 results

Search Page

Filters